DK3436434T3 - Indolin-analoger og anvendelser deraf - Google Patents

Indolin-analoger og anvendelser deraf Download PDF

Info

Publication number
DK3436434T3
DK3436434T3 DK17776297.8T DK17776297T DK3436434T3 DK 3436434 T3 DK3436434 T3 DK 3436434T3 DK 17776297 T DK17776297 T DK 17776297T DK 3436434 T3 DK3436434 T3 DK 3436434T3
Authority
DK
Denmark
Prior art keywords
indolin
analogs
indolin analogs
Prior art date
Application number
DK17776297.8T
Other languages
Danish (da)
English (en)
Inventor
Stephen E Webber
Original Assignee
Oncternal Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncternal Therapeutics Inc filed Critical Oncternal Therapeutics Inc
Application granted granted Critical
Publication of DK3436434T3 publication Critical patent/DK3436434T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/38Oxygen atoms in positions 2 and 3, e.g. isatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK17776297.8T 2016-03-31 2017-03-16 Indolin-analoger og anvendelser deraf DK3436434T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662316156P 2016-03-31 2016-03-31
US201662417621P 2016-11-04 2016-11-04
PCT/US2017/022682 WO2017172368A1 (en) 2016-03-31 2017-03-16 Indoline analogs and uses thereof

Publications (1)

Publication Number Publication Date
DK3436434T3 true DK3436434T3 (da) 2020-09-21

Family

ID=59960688

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17776297.8T DK3436434T3 (da) 2016-03-31 2017-03-16 Indolin-analoger og anvendelser deraf

Country Status (10)

Country Link
US (3) US9822122B2 (enExample)
EP (2) EP3436434B1 (enExample)
JP (2) JP6864379B2 (enExample)
KR (2) KR102375929B1 (enExample)
CN (1) CN109219594B (enExample)
AR (1) AR108010A1 (enExample)
DK (1) DK3436434T3 (enExample)
ES (1) ES2823190T3 (enExample)
TW (2) TWI793070B (enExample)
WO (1) WO2017172368A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388564B (es) 2014-10-09 2025-03-20 Oncternal Therapeutics Inc Compuestos de indolinona y usos de los mismos.
WO2017172368A1 (en) 2016-03-31 2017-10-05 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
CN114569606B (zh) 2016-07-29 2024-04-19 英克特诺治疗公司 吲哚啉酮化合物的用途
TR202002324A2 (tr) * 2020-02-17 2021-08-23 Bahcesehir Ueniversitesi Yeni̇ mouse double minute 2 (mdm2) i̇nhi̇bi̇törü olarak kullanmak i̇çi̇n drg-mdm2-3
CN111518086B (zh) * 2020-05-22 2021-08-06 广州医科大学 氧化吲哚-萘并呋喃衍生物及其制备方法、用途以及包含其的药物组合物、制剂
WO2023178040A2 (en) * 2022-03-13 2023-09-21 University Of Virginia Patent Foundation Inhibitors of ews-fli1
CN115850151A (zh) * 2022-11-25 2023-03-28 成都普康生物科技有限公司 一种席夫碱类似化合物及其合成方法、pi3k激酶抑制剂及其应用
CN115993455A (zh) * 2022-12-29 2023-04-21 南京医科大学康达学院 Rna结合蛋白nova2作为非小细胞肺癌转移标志物的应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3435034A (en) 1967-03-17 1969-03-25 Sandoz Ag Pyridazino(3,4-b)indoles
US3592813A (en) 1967-04-18 1971-07-13 Smith Kline French Lab 3-phenyl-9h-pyridazino(3,4-b)indoles
US3631177A (en) 1967-04-18 1971-12-28 Smith Kline French Lab 3-phenacyl-2-oxoindolines
US4376731A (en) 1978-01-31 1983-03-15 Boehringer Mannheim Gmbh 1-Aziridine carboxylic acid derivatives with immunostimulant activity
DE3483704D1 (de) 1983-07-22 1991-01-17 Du Pont Phenylchinolinsaeure und derivate als antitumormittel.
KR910700237A (ko) 1989-01-23 1991-03-14 리챠드 지. 워터맨 치환된 트리아졸, 그의 제조방법 및 살진균제로서 사용하기 위한 조성물
GB8909737D0 (en) 1989-04-27 1989-06-14 Shell Int Research Thiazole derivatives
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
EP0613890A1 (en) 1993-02-28 1994-09-07 Nihon Nohyaku Co., Ltd. Novel triazole compound, process for preparing the same and antifungal agent containing the same
CA2190708A1 (en) 1995-12-08 1997-06-09 Johannes Aebi Aminoalkyl substituted benzo-heterocyclic compounds
PL336304A1 (en) 1997-04-16 2000-06-19 Abbott Lab 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their application as adenosine kinase inhibitors
EP1135123B1 (en) 1998-12-04 2004-12-29 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
CN1155572C (zh) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US20030114666A1 (en) 2001-06-19 2003-06-19 Ellsworth Edmund Lee Antibacterial agents
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
EP3034510A1 (en) 2004-04-30 2016-06-22 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a c5-modified pyrimidine
BRPI0511524A (pt) 2004-05-25 2007-12-26 Astrazeneca Ab composto ou um sal pró-droga farmaceuticamente aceitável do mesmo, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, composto ou um sal farmaceuticamente aceitável do mesmo, ou um éster hidrolisável in vivo do mesmo, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, ou de um éster hidrolisável in vivo do mesmo, composição faramacêutica, e, processo para a preparação de um composto ou um seu sal farmaceuticamente aceitável, ou de um seu éster hidrolisável in vivo
BRPI0511526A (pt) 2004-05-25 2007-12-26 Astrazeneca Ab composto, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para a preparação de um composto
US7812045B2 (en) 2005-03-30 2010-10-12 Daewoong Pharmaceutical Co., Ltd. Antifungal triazole derivatives
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
US20090217390A1 (en) 2005-04-29 2009-08-27 Fernando Lecanda Cordero Non-human animal sarcoma model
MX2007014811A (es) 2005-06-10 2008-02-14 Boehringer Ingelheim Int Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos.
AU2006295260A1 (en) 2005-08-29 2007-04-05 Gerard M. Housey Theramutein modulators
FR2903984B1 (fr) 2006-07-24 2008-10-03 Genfit Sa Derives d'imidazolones substitues, preparation et utilisations
WO2008046083A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
CA2953987A1 (en) * 2006-12-29 2008-07-10 Georgetown University Targeting of ews-fli1 as anti-tumor therapy
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
WO2008091681A2 (en) 2007-01-23 2008-07-31 Housey Gerard M Theramutein modulators
EP2134721A1 (en) 2007-03-02 2009-12-23 Micurx Pharmaceuticals, Inc. Antimicrobial heterocyclic compounds for treatment of bacterial infections
PL2154966T3 (pl) 2007-04-20 2014-03-31 Univ New York State Res Found Benzoimidazole i ich kompozycje farmaceutyczne
US8377992B2 (en) 2007-10-22 2013-02-19 The Wistar Institute TRBD-binding effectors and methods for using the same to modulate telomerase activity
CA2734154C (en) 2008-08-15 2017-07-11 N30 Pharmaceuticals, Llc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
WO2010033643A2 (en) 2008-09-17 2010-03-25 Burnham Institute For Medical Research Small molecule compounds for stem cell differentiation
US20110218155A1 (en) 2008-10-10 2011-09-08 Dana-Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
MX368109B (es) 2008-10-21 2019-09-18 Onyx Therapeutics Inc Terapia de combinacion con epoxicetonas peptidicas.
US8710068B2 (en) 2009-01-19 2014-04-29 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
KR101149529B1 (ko) 2009-09-11 2012-05-25 한국화학연구원 인덴온 유도체 및 이를 포함하는 약학적 조성물
WO2012003418A2 (en) 2010-07-02 2012-01-05 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine d2 receptors
WO2012021467A1 (en) 2010-08-10 2012-02-16 Metabolic Solutions Development Company, Llc Synthesis for thiazolidinedione compounds
WO2012078519A2 (en) 2010-12-06 2012-06-14 Numerate, Inc. 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
WO2012177603A2 (en) 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN102516152B (zh) 2011-12-12 2014-12-10 华东师范大学 一种α-二氟羰基取代的手性叔醇类化合物及其合成方法和应用
WO2013091096A1 (en) 2011-12-20 2013-06-27 Boehringer Ingelheim International Gmbh Condensed triclyclic compounds as inhibitors of hiv replication
WO2013144224A1 (en) 2012-03-27 2013-10-03 Syngenta Participations Ag Acetylenic microbiocides
US20130259927A1 (en) 2012-04-02 2013-10-03 Gradalis, Inc. Ewing's Sarcoma Bifunctional shRNA Design
NZ723971A (en) 2012-04-12 2018-01-26 Univ Georgetown Methods and compositions for treating ewings sarcoma family of tumors
WO2014015153A2 (en) * 2012-07-20 2014-01-23 Star Biotechnology, Llc Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1
EA201590197A1 (ru) 2012-08-23 2015-07-30 Алиос Биофарма, Инк. Соединения для лечения парамиксовирусных вирусных инфекций
TWI736135B (zh) 2013-03-01 2021-08-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
KR20150143439A (ko) 2013-03-15 2015-12-23 알레간 인코포레이티드 무스카린성 효능제
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CN103435606A (zh) 2013-08-22 2013-12-11 中国药科大学 CDK2与GSK3β双重抑制剂及用途
WO2015061229A1 (en) 2013-10-24 2015-04-30 Georgetown University Methods and compositions for treating cancer
WO2015078929A1 (en) 2013-11-27 2015-06-04 Oncoethix Sa Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
CN105793251B (zh) 2013-12-05 2018-10-12 豪夫迈·罗氏有限公司 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物
AU2015227142A1 (en) 2014-03-07 2016-10-20 Bristol-Myers Squibb Company Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
JP2017514806A (ja) 2014-04-16 2017-06-08 シグナル ファーマシューティカルズ,エルエルシー Torキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
JP6832846B2 (ja) 2014-09-15 2021-02-24 プレキシコン インコーポレーテッドPlexxikon Inc. ヘテロ環化合物およびその用途
MX388564B (es) * 2014-10-09 2025-03-20 Oncternal Therapeutics Inc Compuestos de indolinona y usos de los mismos.
WO2017172368A1 (en) * 2016-03-31 2017-10-05 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
CN114569606B (zh) 2016-07-29 2024-04-19 英克特诺治疗公司 吲哚啉酮化合物的用途

Also Published As

Publication number Publication date
CN109219594A (zh) 2019-01-15
EP3795563B1 (en) 2024-07-17
TW201738209A (zh) 2017-11-01
KR20180123569A (ko) 2018-11-16
JP2021102643A (ja) 2021-07-15
KR102514814B1 (ko) 2023-03-27
US10351569B2 (en) 2019-07-16
ES2823190T3 (es) 2021-05-06
EP3436434A4 (en) 2019-08-28
US20190337951A1 (en) 2019-11-07
TWI793070B (zh) 2023-02-21
KR20220038529A (ko) 2022-03-28
JP2019510069A (ja) 2019-04-11
WO2017172368A1 (en) 2017-10-05
JP7269668B2 (ja) 2023-05-09
AR108010A1 (es) 2018-07-04
US9822122B2 (en) 2017-11-21
TWI786723B (zh) 2022-12-11
JP6864379B2 (ja) 2021-04-28
KR102375929B1 (ko) 2022-03-16
US20170349600A1 (en) 2017-12-07
US20170283420A1 (en) 2017-10-05
TW202140492A (zh) 2021-11-01
CN109219594B (zh) 2022-10-11
EP3436434A1 (en) 2019-02-06
US10711008B2 (en) 2020-07-14
EP3436434B1 (en) 2020-07-08
EP3795563A1 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3333191T3 (da) Anti-C10ORF54-antistoffer og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
EP3563813A4 (en) MOUTHPIECE
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3436434T3 (da) Indolin-analoger og anvendelser deraf
PL3785557T3 (pl) Ustnik
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3337506T3 (da) Kombinationer og anvendelser deraf
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
EP3498837A4 (en) Genome editing method
DE112017004089A5 (de) Al-Gusslegierung
DK3131920T3 (da) Msp-nanoporer og anvendelser deraf
DK3386956T3 (da) Fumagillolderivater og polymorfer deraf
DK3709970T3 (da) Linezolidformuleringer
EP3489155A4 (en) ATTACHED
EP3438306A4 (en) NI-FE-CR ALLOY
DE112017006468A5 (de) Al-gusslegierung
DK3370250T3 (da) Filmform og prægningsfremgangsmåde
EP3470119A4 (en) EXTINGUISHERS
DK3371324T3 (da) Virusbiomarkører og anvendelser deraf
DK3263133T3 (da) Pyridinonforbindelse og anvendelse deraf
HUE066130T2 (hu) Duddingtonia flagranst tartalmazó készítmény